P2176
Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis CElbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis CStructural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection.Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): aEfficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with preElbasvir/Grazoprevir: First Global Approval.Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection.Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C.Grazoprevir + elbasvir for the treatment of hepatitis C virus infection.Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C.Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial.Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection.The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.Projected Clinical And Economic Impact Of Grazoprevir (Gzr, Mk-5172)/Elbasvir (Ebr, Mk-8742) For Chronic Hcv Genotype 1 Infection In Chronic Kidney Disease.The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.Barrier to resistance: lessons from 2 direct-acting hepatitis C virus inhibitors, MK-5172 and Sofosbuvir.The Discovery of Quinoxaline-Based Metathesis Catalysts from Synthesis of Grazoprevir (MK-5172)
P921
Q26740233-BD160AF3-E7FC-43FC-9942-1E50607BC049Q26741123-63A5521F-F714-479D-A3EE-333F35646937Q27703170-4A9A18AA-2A62-4290-B479-25D26452276BQ34411907-B3D4E1B1-084D-4EE9-85CD-C453A7814579Q34451681-3F0E5D67-FD3A-44D9-81ED-498ACAFD2EFBQ34451707-C17346F1-151E-46BC-97E4-D4CFA6D19981Q34516975-B006D5C0-7234-4C8B-9C66-FB7C7F22F5F4Q38714156-DD518CB0-C71B-492D-8587-40403116E25DQ38724091-6A894179-83E7-4713-B0DB-9818F3F6BD43Q38757717-F290A832-4041-48E8-92DF-C2F7E0F7F478Q38811486-799813F2-FCF3-4FC8-A108-7401E584031AQ40481513-730BAAE2-09A7-40DE-AF28-C611C3053D39Q40557598-E865F3EA-9A76-4D09-A7A1-6EECBBD06B6FQ40705885-BCE23D66-0C1B-43E6-A73B-CE4FAD02E61AQ40773451-0789FF6E-19CD-4580-A3D3-72C894F356AEQ40924034-D8860AC3-2BCC-45D7-BE21-A393FF89240DQ42224935-9F851CDA-7AE9-4312-8D99-1BFB66CF2ABAQ45344772-74797CF5-4C1F-469E-A57B-53E2D6CA39DEQ89313715-23CF84D9-D0CA-4AC1-8F0C-A01EF7C88C5B
P921
description
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Grazoprevir
@de
Grazoprevir
@es
Grazoprevir
@it
Grazoprevir
@vi
grazoprevir
@en
grazoprewir
@pl
غرازوبريفير
@ar
type
label
Grazoprevir
@de
Grazoprevir
@es
Grazoprevir
@it
Grazoprevir
@vi
grazoprevir
@en
grazoprewir
@pl
غرازوبريفير
@ar
altLabel
MK-5172
@en
grazoprevir anhydrous
@en
prefLabel
Grazoprevir
@de
Grazoprevir
@es
Grazoprevir
@it
Grazoprevir
@vi
grazoprevir
@en
grazoprewir
@pl
غرازوبريفير
@ar
P638
P486
P592
P6366
P661
P662
P683
P117
P2017
COC1=CC2=NC3=C(CCCCC[C@@H]4C[C ...... (=O)C7CC7)O3)C(C)(C)C)N=C2C=C1
P2067
P2115
N0000192395
P2175
P231
1350514-68-9
P233
CC(C)(C)C1C(=O)N2CC(CC2C(=O)NC ...... (=C6)OC)N=C5CCCCCC7CC7OC(=O)N1
P234
1S/C38H50N6O9S/c1-6-22-19-38(2 ...... ,22-,24-,29+,30-,31-,38-/m1/s1
P235
OBMNJSNZOWALQB-NCQNOWPTSA-N
P274
C₃₈H₅₀N₆O₉S